Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study
Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carlo AltamuraUniversity of Milan, Department of Psychiatry, Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, ItalyBackground: Escitalopram is a selective serotonin re...
Guardado en:
Autores principales: | Dell'Osso B, Arici C, Dobrea C, Camuri G, Benatti B, Altamura AC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a8b909c40d56453eadc60169f33f3b5a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ten-year outcome of vagus nerve stimulation-implanted patients with treatment-resistant depression: two Italian cases
por: Dell'Osso B, et al.
Publicado: (2018) -
Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial
por: Martin P. Paulus, et al.
Publicado: (2021) -
Safety of escitalopram in pregnancy: a case series
por: Bellantuono C, et al.
Publicado: (2013) -
Duloxetine in panic disorder with somatic gastric pain
por: Preve M, et al.
Publicado: (2013) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)